

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) ~~Use of a~~ A method for increasing the number of islets of Langerhans cells, treatment of prediabetes, treatment or prevention of insulin-dependent diabetes, prevention of non-insulin-dependent diabetes, or treatment of early non-insulin-dependent diabetes, comprising administering to a patient in need thereof an effective amount of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for increasing the number of islets of Langerhans cells.

2. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor~~ A method according to Claim 1, wherein in increasing the number of islets of Langerhans cells, the patient is in need of in the context of the treatment and/or or prevention of diabetes, its complications and/or its or a complication thereof or a related pathologies pathology thereof.

3. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament~~ A method according to claim 1, which is for the treatment of prediabetes.

4. (Currently Amended) ~~Use~~ A method according to Claim 3, ~~for which the~~ wherein said prediabetes is an insulin-dependent prediabetes.

5. (Currently Amended) ~~Use~~ A method according to Claim 3, ~~for which the~~ wherein said prediabetes is a non-insulin-dependent prediabetes.

6. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for the~~ A method according to claim 1, which is for the treatment and/or or prevention of insulin-dependent diabetes.

7. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament~~ A method according to claim 1, which is for the prevention of non-insulin-dependent diabetes.

8. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament~~ A method according to claim 1, which is for the treatment of early non-insulin-dependent diabetes.

9. (Currently Amended) ~~Use~~ A method according to claim 3, ~~for which the said treatment or prevention is by increasing~~ wherein the number of islets of Langerhans cells are increased.

10. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor in combination with one or more immunosuppressants, for the manufacture of a medicament~~ A method according to claim 1, which is for the prevention ~~and/or~~ or treatment of insulin-dependent diabetes, further comprising administering an immunosuppressant.

11. (Currently Amended) ~~Use~~ A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has an impairment in the number of islets of Langerhans cells.

12. (Currently Amended) ~~Use~~ A method according to Claim 11, ~~for which the~~ wherein said patient shows a decrease in the number of islets of Langerhans cells of at least 40%.

13. (Currently Amended) ~~Use~~ A method according to Claim 11, ~~for which the~~ wherein said patient shows a decrease in the number of islets of Langerhans cells of ~~between 50% and to~~ 90%.

14. (Currently Amended) ~~Use~~ A method according to claim 1, ~~wherein the~~ which is suitable for the said treatment and/or the said prevention in the case of a patient ~~with~~ has glucose intolerance.

15. (Currently Amended) ~~Use~~ A method according to Claim 14, ~~for which the~~ wherein said patient presents a fasting glycaemia of ~~between 1.10 g/l and to~~ 1.26 g/l and a glycaemia after meals a meal of ~~between 1.40 g/l and to~~ 2 g/l ~~after meals~~.

16. (Currently Amended) ~~Use~~ A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has one or more anti-islets of Langerhans cells immunological markers.

17. (Currently Amended) Use A method according to Claim 16, ~~for which the~~ wherein said marker(s) indicate(s) the existence of an autoimmune response of the body directed against the antigenic markers of the body's islets of Langerhans cells.

18. (Currently Amended) Use A method according to Claim 16, ~~for which the~~ wherein said marker(s) is (are) ~~chosen from the~~ anti-islet (ICA), anti-glutamic acid decarboxylase (GAD), anti-tyrosine phosphatase (IA-2) ~~and~~ or anti-(pro)insulin (AIA) auto-antibodies, or the anti-carboxypeptidase H, anti-64kD ~~and~~ or anti-heat shock protein antibodies.

19. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has insulin resistance.

20. (Currently Amended) Use A method according to Claim 19, ~~for which the~~ wherein said patient responds partially or not at all to insulin secreted by the beta cells or injected.

21. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient presents a level of glycated haemoglobin of higher than 7%.

22. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient has islets of Langerhans cells showing an anomaly of insulin secretion in response to glucose.

23. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient presents a suppression of the early peak of insulin secretion.


24. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient shows related hyperglycaemia and obesity.

25. (Currently Amended) Use A method according to Claim 24, ~~for which the~~ wherein said patient suffers from paediatric obesity.

27. (Currently Amended) Use A method according to Claim 25, ~~for which the~~ wherein said risk factor is ~~chosen from~~ familial history, gestational diabetes, excess weight, obesity, insufficient physical exercise, high blood pressure, a high level of triglycerides, hyperlipidaemia and or inflammation.


29. (Currently Amended) ~~Process~~ A process for increasing the number or the insulin-secreting capacity of islets of Langerhans cells, comprising the in vitro application of a kynurenine 3-hydroxylase inhibitor to ~~the~~ said cells.


33. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said kynurenine 3-hydroxylase inhibitor is a compound of the general formula (I) or (II):



(11)

- W represents a divalent radical chosen from the following radicals:





• R<sup>1</sup> represents a ~~radical chosen from~~ linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and~~ or an optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, a heterocyclic radical, an aryl radical ~~and~~ or a heteroaryl radical;

• R<sup>2</sup> is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxy carbonyl, aryl, heteroaryl, cycloalkyl ~~and~~ or a heterocyclic radical;

• R<sup>3</sup> is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, cycloalkyl ~~and~~ or a heterocyclic radical;

• R<sup>2</sup> and R<sup>3</sup> together ~~also possibly forming a group~~ optionally form =CR<sup>16</sup>R<sup>17</sup>; or alternatively together ~~forming~~ form, with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

• R<sup>4</sup> is ~~chosen from~~ hydroxyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, -N(R<sup>12</sup>R<sup>12'</sup>), -N(R<sup>12</sup>)OR<sup>13</sup>, linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and~~ or an optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl ~~and~~ or a heterocyclic radical;

• R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup>, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, ~~and~~ or a nitro, cyano, hydroxyl, trifluoromethyl, alkyl, alkoxy, cycloalkyl or aryl radical;

• the radicals R<sup>5</sup> and R<sup>6</sup>, ~~on the one hand~~, or R<sup>6</sup> and R<sup>7</sup>, ~~on the other hand~~, may also form, together with the carbon atoms to which they are attached, a benzene ring optionally substituted by one or more groups, which may be identical or different, ~~chosen from~~ and are a halogen atom, a trifluoromethyl, cyano or nitro radical, an alkyl radical ~~and~~ or an alkoxy radical;

• R<sup>9</sup> represents hydrogen or an alkyl radical;

• R<sup>10</sup> is ~~chosen from~~ an alkyl, an aryl ~~and~~ or a heteroaryl radical;

• R<sup>12</sup> and R<sup>12'</sup>, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen ~~and~~ or an alkyl, alkenyl, alkynyl, alkylcarbonyl, aryl or heteroaryl radical; or alternatively R<sup>12</sup> and R<sup>12'</sup> may form, together with the nitrogen atom to which they are attached, a monocyclic or bicyclic heterocyclic group containing a total of 5 to 10 atoms, among which 1, 2, 3 or 4 are ~~chosen~~, independently of each other, ~~from~~ nitrogen, oxygen ~~and~~ or sulfur,

the said heterocyclic radical also optionally comprising 1, 2, 3 or 4 double bonds and optionally being substituted by one or more ~~chemical~~ groups, which may be identical or different, ~~chosen from~~ and are hydroxyl, halogen atom, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclic radical ~~and or~~ trifluoromethyl;

- $R^{13}$  is ~~chosen from~~ hydrogen ~~and or~~ an alkyl, alkenyl, alkynyl, aryl, heteroaryl, -N( $R^{12}R^{12'}$ ) or -N( $R^{12}$ )OR $^{13}$  radical;

- $R^{14}$  is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- $R^{14}$  may ~~also~~ form a bond with  $R^2$ , thus forming a double bond between the carbon atoms respectively bearing the substituents  $R^{14}$  and  $R^2$ ; or alternatively  $R^{14}$  forms, with  $R^2$  and with the carbon atoms that bear them, a ring containing a total of 3, 4, 5, 6 or 7 carbon atoms, among which 1, 2 or 3 may be replaced with ~~an atom chosen from~~ nitrogen, oxygen ~~and or~~ sulfur, the said ring ~~possibly~~ optionally comprising one or more unsaturations in the form of (a) double bond(s), and being optionally substituted by one or more radicals, which may be identical or different, ~~chosen from~~ and are oxo, alkoxy, alkoxycarbonyl ~~and or~~ alkylcarbonyloxy;

- $R^{15}$  is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkoxycarbonyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclylthio, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- $R^{14}$  and  $R^{15}$  ~~also possibly forming~~ optionally form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

- $R^{16}$  and  $R^{17}$ , which may be identical or different, ~~are chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, an alkyl, aryl, heteroaryl or cycloalkyl radical ~~and or~~ a heterocyclic radical; or alternatively

- $R^{16}$  and  $R^{17}$  form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical; and

- $R^{11}$  is ~~chosen from~~ hydrogen ~~and or~~ an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl radical, ~~and any~~ or a protecting group for an amine function;

~~and also the possible~~ or a geometrical ~~and/or~~ or optical ~~isomers~~ isomer thereof, ~~and possi-~~

ble or a tautomeric forms form thereof;

~~the solvates and hydrates of these compounds; or a solvate or hydrate thereof; or a~~  
~~and also the possible salts salt~~ thereof with a pharmaceutically acceptable acid or base, or  
~~alternatively the a pharmaceutically acceptable prodrugs of these compounds~~ prodrug thereof.

34-54. (Cancelled)

55. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase.

56. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase in an *in vitro* test.